NITO
N2OFF, Inc.·Basic Materials
4.12
3.778%(+0.15)
Market ClosedLast Updated: — ET
52W L: $0.5752W H: $29.40
NITO NEWS
defenseworld.net
Mar 23
Forafric Global (NASDAQ:AFRI) & N2OFF (NASDAQ:NITO) Financial Contrast
N2OFF (NASDAQ: NITO - Get Free Report) and Forafric Global (NASDAQ: AFRI - Get Free Report) are both small-cap consumer staples companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings and valuation. Volatility and Risk N2OFF has a beta
defenseworld.net
Mar 4
N2OFF (NASDAQ:NITO) Shares Up 5.4% – Still a Buy?
N2OFF, Inc. (NASDAQ: NITO - Get Free Report) shares were up 5.4% on Tuesday. The stock traded as high as $1.00 and last traded at $0.9828. Approximately 42,228 shares changed hands during mid-day trading, a decline of 81% from the average daily volume of 222,978 shares. The stock had previously closed at $0.9324. N2OFF Stock
globenewswire.com
Feb 25
N2OFF Announcing Corporate Rebranding as Nexentis Technologies - Innovative AI and Data Driven Computational Biotech Company
New identity reflects Company's evolution into an innovative data driven biotech company leveraging MITOLINE and mitochondrial carrier biology across oncology and inflammatory metabolic diseases Neve Yarak, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) ("N2OFF" and the "Company"), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, today announced a comprehensive corporate rebranding to Nexentis Technologies Inc.
thenewswire.com
Feb 19
N2OFF, Inc. Provides Early Warning Disclosure
Vancouver, British Columbia, February 19, 2026 – TheNewswire – This press release is being disseminated as required b y National Instrument 62-103 The Early Warning System and Related Take-Over Bid and Insider Reporting Issues (“NI 62-103”). The requirement to provide this disclosure was triggered by an increase in Plantify Foods, Inc.'s (“ Plantify ”) issued and outstanding share capital on February 18, 2026, as a result of the closing of a Private Placement.
globenewswire.com
Feb 2
In Spaceflight Conditions: N2OFF‘s MitoCareX Bio Highlights Co-Founder's Innovative Research on Mitochondrial Carriers in Microgravity and Cosmic radiation Conditions
Neve Yarak, Israel, Feb. 02, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, today highlighted a newly published peer-reviewed study co-authored by Prof. Ciro Leonardo Pierri, co-founder of MitoCareX Bio Ltd. (“MitoCareX Bio”), a specialty biotechnology company developing small‑molecule drugs that target human mitochondrial carriers, its wholly- owned subsidiary. The article, appearing in the Journal of Translational Medicine, investigates SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets for dysfunctions induced by spaceflight conditions, including microgravity and cosmic radiation.
globenewswire.com
Jan 22
N2OFF: MitoCareX Bio Announces Positive In Vitro Results from Its Mitochondrial Carrier Small Molecule Platform
MITOLINE™ Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for Inflammatory Metabolic Diseases – A Market Projected to Exceed $120 billion by 2030
